

DMD #23655

Decreased Susceptibility of the Cytochrome P450 2B6 Variant K262R to Inhibition by Several Clinically Important Drugs

Jyothi C. Talakad, Santosh Kumar, and James R. Halpert

Skaggs School of Pharmacy & Pharmaceutical Sciences,

University of California San Diego,

9500 Gilman Drive, La Jolla, CA 92093 (JCT, SK, JRH)

DMD #23655

Running Title: Altered drug interaction with the P450 2B6 K262R variant

Corresponding Author:

Santosh Kumar, Division of Pharmacology and Toxicology, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte St. Kansas City, MO 64108

Phone: 816-235-5494, Fax: 816-235-1776, Email: kumarsa@umkc.edu

Number of text pages: 24

Number of Tables: 2

Number of Figures: 4

Number of References: 29

Number of words in Abstract: 250

Number of words in Introduction: 425

Number of words in Discussion: 614

Abbreviations:

CYP, cytochrome P450; 7-MFC, 7-methoxy-4-(trifluoromethyl)coumarin; CPR, NADPH-cytochrome P450 reductase; b_5 , cytochrome b_5 ; SNP, single nucleotide polymorphism; CSM, conserved sequence motif; DDI, drug-drug interaction ; AUC, area under plasma concentration

Abstract

Cytochrome P450 (CYP) 2B6 metabolizes a number of clinically relevant drugs and is one of the most highly polymorphic human P450 enzymes, with the Lys²⁶²→Arg substitution being especially common in several genetic variants. Therefore, K262R (2B6*4) was created in the CYP2B6dH background (N-terminal modified and C-terminal His tagged) and expressed in *E. coli*. The recombinant CYP2B6dH and K262R were purified and studied to investigate the effect of the Lys²⁶²→Arg substitution with six of the most potent drug inhibitors of CYP2B6, namely clopidogrel, clotrimazole, itraconazole, raloxifene, sertraline and ticlopidine. K262R showed a > 3-fold increase in the K_i values with clopidogrel, itraconazole, and raloxifene and ~ 6-fold increase in K_i with sertraline, compared with CYP2B6dH. Similarly, K262R showed 2-, 4-, and > 20-fold higher K_s values than CYP2B6dH with clopidogrel, sertraline, and itraconazole, respectively. In contrast, when tested with several known type II inhibitors of CYP2B enzymes, K262R showed a 10-fold lower IC_{50} with 4-(phenyl)pyridine and ~2-fold lower IC_{50} with 4-(4-nitrobenzyl)pyridine or 1-(4-phenyl)benzylimidazole than CYP2B6dH. Subsequent analysis predicted possible in vivo drug-drug interactions between the CYP2B6 substrate efavirenz and drug inhibitors clopidogrel, clotrimazole, itraconazole, sertraline, and ticlopidine. Furthermore, Q172H/K262R (2B6*6), which is the most common genetic variant of CYP2B6 harboring K262R, was created in CYP2B6dH, expressed, purified, and characterized for inhibition. Q172H/K262R showed a > 6-fold increase in K_i with sertraline and clopidogrel compared with CYP2B6dH. The results suggest that individuals, especially homozygotes, with the 2B6*4 or 2B6*6 allele might be less susceptible to drug interactions resulting from P450 inhibition.

Introduction

Although cytochrome P450 2B6 (CYP2B6) is expressed at relatively low levels in the liver (Guengerich, 2005), the enzyme metabolizes important pharmaceuticals including cyclophosphamide, propofol, promazine, methadone, *S*-mephenytoin, efavirenz, bupropion, imipramine, midazolam, artemisinin, and tamoxifen (Rendic, 2002; Lewis et al., 2004; Zanger, et al., 2007). In addition, CYP2B6 possesses several important genetic variants; among them the most common are K262R (2B6*4), Q172H/K262R (2B6*6) and R487C (2B6*5). Frequencies of the three most common single nucleotide polymorphisms (SNPs) range from 14-49% for Q172H, 17-63% for K262R, and 0-14% for R487C depending on the ethnicity of the population studied (Lang et al., 2004). For example, studies in German males have found a K262R allele frequency of approximately 5% and a SNP frequency of 30% (Lang et al., 2001; Kirchheiner et al., 2003). Single-dose bupropion pharmacokinetic data obtained from 121 individuals showed 1.3-fold increased clearance by individuals with the 2B6*1/*4 genotype (Kirchheiner et al., 2003). A similar study of 169 individuals with efavirenz showed a 17% reduced area under plasma concentration (AUC) in *1/*4 heterozygotes (Rotger et al., 2007). In vitro, K262R has been incorporated into the engineered CYP2B6dH (N-terminal deleted and C-terminal His-tag) by Hollenberg's group to study structure-function. Compared with CYP2B6dH, K262R shows a > 2-fold increased k_{cat} for the metabolism of bupropion to hydroxybupropion (Bumpus et al., 2005) and ~ 2-fold increased catalytic efficiency for the metabolism of efavirenz to 8-hydroxyefavirenz (Bumpus et al., 2006). Interestingly, in contrast to CYP2B6dH, K262R is refractory to mechanism-based inactivation by 17 α -ethynylestradiol or efavirenz, whereas susceptibility of the variant to inactivation is preserved with bergamottin, *N,N',N''*-

DMD #23655

triethylenethiophosphoramidate and 8-hydroxyefavirenz (Bumpus et al., 2005; Bumpus et al., 2006).

Drug-drug interactions (DDIs), especially through inhibition of P450-mediated drug metabolism by a co-administered drug, are one of the primary causes of serious adverse events occurring in clinical practice (Dambro and Kallgren, 1988). The presence of polymorphic variants of P450 further complicates the prediction of in vivo DDIs. To address the issues of genotype-dependent DDIs as a result of enzyme inhibition, Tracy and colleagues have used five substrates and a battery of inhibitors with CYP2C9.1 and CYP2C9.3 variants (Kumar et al., 2006). Recently, several clinically relevant drugs, such as clopidogrel, clotrimazole, itraconazole, ticlopidine, sertraline, and raloxifene have been found to be potent inhibitors of CYP2B6 (Walsky et al., 2006). Therefore, in the present study we have studied the effect of the Lys²⁶²→Arg substitution in K262R (2B6*4) and Q172H/K262R (2B6*6) genetic variants on the susceptibility of CYP2B6dH to inhibition by important clinical drugs, and predicted the effect on metabolism of the marker CYP2B6 substrate efavirenz in vivo.

DMD #23655

Materials and Methods

Materials. 7-Methoxy-4-(trifluoromethyl) coumarin (7-MFC) and 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) were purchased from Invitrogen (Carlsbad, CA). NADPH, drug compounds, and most of the pyridine and imidazole inhibitors were bought from Sigma Chemical Co. (St. Louis, MO). 5-Cyclohexylpentyl- β -D-maltoside (CYMAL-5) was from Anatrace (Maumee OH). Recombinant NADPH cytochrome P450 reductase (CPR) and cytochrome b_5 (b_5) from rat liver were prepared as described previously (Harlow et al., 1997). Oligonucleotide primers for polymerase chain reaction were obtained from Sigma Genosys (Woodlands, TX). The molecular chaperone plasmid pGro7, which expresses GroES/EL (Nakajima et al., 1994), was obtained from TAKARA BIO (Shiba, Japan). The QuikChange Site Directed Mutagenesis kit was obtained from Stratagene (La Jolla, CA). Ni-NTA affinity resin was purchased from Qiagen (Valencia, CA). All other chemicals were of the highest grade available and were obtained from standard commercial sources.

Mutagenesis, Expression, and Purification. To create K262R, CYP2B6dH was used as the template, and the forward and reverse primers were 5'-CCCAGCGCCCCCAGGGACCTCATCGAC-3' and 5'-GTCGATGAGGTCCCTGGGGGCGCTGGG-3', respectively. For Q172H/K262R, K262R was used as the template, and the forward and reverse primers were 5'-ACCTTCCTCTTCCATTCCATTACCGCC-3' and 5'-GGCGGTAATGGAATGGAAGAGGAAGGT-3', respectively. The resulting constructs were sequenced to verify the desired mutations and absence of unintended mutations (K262R and Q172H/K262R were analyzed at Protein Chemistry Laboratory, University of Texas Medical Branch, Galveston, TX and Retrogen, Inc., San Diego, CA. respectively). CYP2B6dH, K262R,

DMD #23655

and Q172H/K262R were co-expressed with GroES/EL in *JM109* cells (Stratagene, La Jolla, CA) as described previously (Kumar et al., 2007). The proteins were then extracted and purified by modifying the recently described procedure (Kumar et al., 2007). In brief, the cell extract was loaded onto Ni-NTA resin in the presence of the detergent CYMAL-5. Protein was eluted with 10 mM KPi, pH 7.4, containing 100 mM NaCl, 20% glycerol, 10 mM β -mercaptoethanol, 0.5 mM phenylmethylsulphonyl fluoride, and 40 mM histidine. CYMAL-5 was added to 4.8 mM, and the sample was subsequently loaded onto a CM-Sepharose column. After washing the CM-Sepharose column using 10 mM KPi buffer containing 0.2 mM DTT, 1 mM EDTA, 20% glycerol, and 100 mM NaCl, the protein was eluted using 500 mM NaCl in the above buffer. Eluted protein was dialyzed against 10 mM KPi buffer containing 10% glycerol and 1 mM EDTA with three changes. The P450 content was measured by reduced CO-difference spectra. Protein concentrations were determined using the Bradford protein assay kit (BioRad, Hercules CA).

Enzyme Inhibition. 7-MFC *O*-deethylation was measured in a final reaction volume of 100 μ l as described earlier (Oezguen et al., 2008). In brief, the reaction mixture contained 150 μ M 7-MFC in the standard reconstitution system (P450: CPR: b_5 , 1:4:2) at 5 pmol P450 in 50 mM Hepes, pH 7.4, 15 mM $MgCl_2$, and 2% MeOH. The reaction was performed at 37 °C for 5 min using 1 mM NADPH. Nonlinear regression analysis was performed to fit the data using a four-parameter logistic function to derive the IC_{50} values for all the imidazole and pyridine derivatives. The K_i values were determined using the 7-MFC *O*-deethylation assay in a final reaction volume of 100 μ l at 0.5-5.0 μ M drug concentrations and 0-50 μ M substrate concentrations. For all inhibition studies, 10 pmol P450 was used. The K_i was determined using global fit for competitive inhibition from SpectraLab.

DMD #23655

Spectral Binding. For binding studies, difference spectra were recorded using 1 μ M P450 on a Shimadzu 2401 PC spectrophotometer at 25 °C as described earlier (Muralidhara et al., 2006). In brief, difference in absorbance between the maxima and minima (ΔA) was recorded after the addition of a series of inhibitor concentrations in methanol to the sample cuvette and the same amount of methanol to the reference cuvette. The spectral dissociation constants (K_s) were obtained by fitting the data to the equation for “tight binding” $2\Delta A = (\Delta A_{\max} / [E_0]) ((K_D + [I_0] + [E_0]) + ((K_D + [I_0] + [E_0])^2 - 4[E_0][I_0])^{1/2})$. All data treatment and fitting of the inhibition and titration curves were performed with our SpectraLab software.

Analysis of DDIs. The analysis for DDIs was carried out essentially as described by Tracy and colleagues (Kumar et al., 2006). In brief, the values for plasma concentrations (C_{\max}) of efavirenz as [S], and of drug inhibitors as [I] in a normal population were taken from the literature. The K_i values were from this investigation, and k_{cat} and K_m values for efavirenz hydroxylation were obtained from a previous study as follows: $k_{\text{cat}} = 4.3$ and 7.9 min^{-1} and $K_m = 14.3$ and $15.9 \mu\text{M}$ for CYP2B6dH and K262R, respectively (Bumpus et al., 2006). These values for CYP2B6dH or K262R were fit to the equation for competitive inhibition to determine the predicted in vivo activity of the enzyme. The plasma concentrations of efavirenz and drug inhibitors are not known in the population harboring K262R, and therefore, we have used the concentrations as reported in the normal population.

DMD #23655

Results

Expression and Thermal Stability of CYP2B6dH and K262R. Heterologous expression of CYP2B6 and genetic variants such as M46V, G99E, K139E, Q172H, K262R, R140Q, and I391N in COS-1 cells yielded lower P450 expression, suggesting decreased P450 stability (Lang et al., 2004). Therefore, we investigated P450 expression of K262R (2B6*4) as described previously (Kumar et al., 2007). The expression of K262R in *E. coli* under our standard conditions was ~1.5-fold higher than CYP2B6dH. However, the thermal stability (T_m) of K262R was 2 °C lower than CYP2B6dH (Supporting fig. 1). The results suggest no major difference in the expression or stability of K262R compared with the wild-type. In this study, we used the dH construct because it shows much higher bacterial expression and solubility, and more facile purification than the full-length wild-type.

Inhibition and Spectral Binding of CYP2B6dH and K262R by Drugs. To investigate the effect of the Lys²⁶²→Arg substitution on the interaction with the most potent drug inhibitors of CYP2B6 (Walsky et al., 2006), we selected clopidogrel, ticlopidine, clotrimazole, itraconazole, sertraline, and raloxifene (Supporting fig. 2). The results are presented in Figure 1 and Table 1. The K_i values were determined for competitive inhibition of CYP2B6dH and K262R by the six drugs using 7-MFC at concentrations up to 50 μM and 0-20 μM inhibitor concentrations. The k_{cat} and K_m values for 7-MFC oxidation were 3.8 min⁻¹ and 5.1 μM for CYP2B6dH and 4.9 min⁻¹ and 5.0 μM for K262R, respectively. CYP2B6dH and K262R showed similar K_i values with clotrimazole and ticlopidine (Fig. 1 and Table 1). However, K262R showed a > 3-fold increase in the K_i values with clopidogrel, itraconazole, and raloxifene compared with CYP2B6dH. In addition, K262R showed ~ 6-fold increase in K_i with sertraline compared with CYPB6dH.

Clopidogrel, ticlopidine, itraconazole, and sertraline induced type I difference spectra with a peak at ~388 nm and a trough at ~420 nm (Fig. 2 inset). CYP2B6dH and K262R showed similar ΔA_{\max} values with clopidogrel, itraconazole, and ticlopidine, whereas the ΔA_{\max} with sertraline was 3-fold higher in K262R than the wild-type. Compared with CYP2B6dH, K262R showed approximately 2-, 4-, and 20-fold higher K_s values with clopidogrel, sertraline, and itraconazole, respectively (Fig. 2, Table 1). No significant changes were observed in the K_s values of ticlopidine between CYP2B6dH and K262R. However, the experiment could not be performed with raloxifene because it interfered with the measurement of the type I spectral change. At lower concentration of clotrimazole, the majority of CYP2B6dH and K262R P450 was converted into P420 (data not shown).

Analysis of DDIs in CYP2B6dH and K262R. Clopidogrel, sertraline, and raloxifene are among the top 100 prescribed drugs in seniors (<http://www.marylandspdap.com>), who often use multiple drugs simultaneously, suggesting possible drug-drug interactions. Therefore, we analyzed possible DDIs between the established marker drug substrate of CYP2B6, efavirenz, and drug inhibitors of CYP2B6 clopidogrel, ticlopidine, clotrimazole, itraconazole, sertraline, and raloxifene. The analysis was carried out as described in Materials and Methods. The results predicted that while raloxifene would not alter efavirenz metabolism in vivo, clopidogrel or clotrimazole would almost completely abolish the metabolism of efavirenz (remaining activity = 2% and 6%, respectively) by CYP2B6 (Table 2). In addition, the metabolism of efavirenz would be reduced to 15%, 48%, and 57% in the presence of ticlopidine, sertraline, and itraconazole, respectively (Table 2). Although the Lys²⁶²→Arg substitution would not alter the inhibition significantly in most cases, the substitution is predicted to reduce the metabolism of efavirenz to

DMD #23655

a lesser extent in the presence of itraconazole (20 vs. 43% inhibition) and sertraline (16 vs. 52% inhibition).

Inhibition of Q172H/K262R by Clopidogrel and Sertraline. Because of the low allele frequency of 2B6*4 and few if any homozygotes, we performed selected inhibition studies with the most common variant harboring K262R, namely Q172H/K262R (2B6*6). This haplotype is found with high frequency (14-62%) as summarized by Zanger and colleagues (Zanger et al., 2007) and 21-60% (Rotger et al., 2007). The latter study reported 10% *6/*6 homozygotes. Clopidogrel and sertraline showed 4- and 6-fold higher K_i values, respectively, with K262R than CYP2B6dH, and therefore, the drugs were tested with Q172H/K262R. The results are presented in Figure 3. Q172H/K262R showed a 6-fold increase in the K_i value with clopidogrel (0.6 μ M vs. 0.1 μ M) and > 7-fold increase in the K_i value with sertraline (2.2 μ M vs. 0.3 μ M) compared with CYP2B6dH. The results suggest that the binding affinity of Q172H/K262R with clopidogrel (Figure 3A) and sertraline (Figure 3B) was further reduced compared with K262R. For reference, the k_{cat} and K_m values for 7-MFC oxidation by Q172H/K262R were 1.3 min⁻¹ and 49 μ M, which are > 2-fold lower and ~10-fold higher, respectively, than the corresponding values for CYP2B6dH or K262R.

Inhibition of CYP2B6dH and K262R by Pyridine and Imidazole Derivatives. We also investigated whether K262R shows altered inhibition by the known CYP2B4dH imidazole (Muralidhara et al., 2006) and CYP2B6 pyridine (Korhonen et al., 2007) type II inhibitors. Four compounds from each imidazole and pyridine groups were selected. Compared with CYP2B6dH, K262R showed a 10- fold lower IC_{50} values with 4-(phenyl)pyridine and 2- fold lower IC_{50} values with 4-(4-nitrobenzyl)pyridine and 1-(4-phenyl)benzylimidazole (Supporting

DMD #23655

table 1). It is intriguing that with these two model type II inhibitors, the Lys²⁶²→Arg substitution increased affinity unlike with the drugs.

Molecular Modeling of CYP2B6dH. A CYP2B6dH homology model was generated using the 4-(4-chlorophenyl) imidazole-bound CYP2B4dH structure (1SUO) as a template by energy minimization using Insight III, and was represented using Pymol graphics (<http://pymol.sourceforge.net/>) (Fig. 4). Residues 172 and 262 are located in helix E and the G-H loop, respectively. Interestingly, CYP2B4 and CYP2B11 have a His residue at position 172, whereas CYP2B1, CYP2B4, and CYP2B11 enzymes have an Arg residue at 262, suggesting a possible specific role for Gln-172 or Lys-262 in CYP2B6. A molecular model of CYP2B6dH does not predict a role of residue 262 in substrate binding, except that the side chains of Lys and Arg have different orientations. Further in silico analysis suggests that Arg-262 interacts with His-252 (G-helix), Thr-255 (G-helix), and Asp-266 (H-helix) through H-bonds. These H-bonds are not found in Lys-262 suggesting that the additional interactions in K262R contribute to altered drug binding. Recently, we have shown the importance of H-bonds in CYP2B4dH among the non-active site residues Glu-149, Asn-177, Arg-187, and Tyr-190 in substrate specificity, inhibitor selectivity, and protein stability (Oezguen et al., 2008).

DMD #23655

Discussion

In this study the recombinant CYP2B6dH, K262R, and Q172H/K262R provided new insights into the interactions of the enzyme with clinically relevant drugs. First, by determining K_i values, we verified and extended previous findings of potent inhibition of CYP2B6 derived from IC_{50} values in liver microsomes or Sf9 cells. Second, the competitive nature of the inhibition shown in our experiments was substantiated by spectral binding assays with four of the drugs, which showed typical Type I spectra. Third, decreased inhibitor potency of clopidogrel, itraconazole, raloxifene, and sertraline for K262R is in contrast to increased potency of three small type II inhibitors. Fourth, the role of the non-active site residue at position 262 in CYP2B6 is consistent with our recent conserved sequence motif analysis of CYP family 2 enzymes. Finally, the lower inhibitor potency of sertraline and clopidogrel for K262R (CYP2B6*4) alone and especially in combination with Q172H (CYP2B6*6) suggests the real possibility of a diminished genotype-dependent drug interaction in vivo.

An earlier report showed that itraconazole yields a type II spectrum with CYP3A4 and can adopt multiple orientations within the CYP3A4 active site, including a catalytically productive mode (type I) and a slowly dissociating inhibitory mode (type II) (Pearson et al., 2006). However, a type I spectrum is observed with CYP2B6dH and K262R, suggesting that the orientation of itraconazole is such that the nitrogen of the ligand is not able to coordinate with the heme iron of the protein. The difference in the mode of binding of itraconazole in CYP3A4 and CYP2B6dH may contribute to the differences in their K_s values (0.019 vs. 0.07 μ M, respectively). A relatively large and flexible active site of CYP3A4 may facilitate the multiple modes of interactions with itraconazole.

DMD #23655

Although molecular modeling suggests that Lys-262 in CYP2B6 does not contact ligands directly, this residue is found within a conserved sequence motif (CSM) in CYP family 2 enzymes (²⁶¹PRDFIDVY²⁶⁸). This motif (CSM 11) is only present in the CYP2B and CYP2C subfamilies, where it has a very high rank order of conservation (Oezguen et al., 2008). In addition, analysis of the individual residues showed that Arg-262 is among the most conserved residues within CSM 11, further suggesting its functional and/or structural importance. Interestingly, Leu-264 is also among the most conserved residues within the motif (Oezguen et al., 2008), and a Leu²⁶⁴→Phe substitution in CYP2B6dH enhances P450 expression and thermal stability (Kumar et al., 2007).

Because ticlopidine and clopidogrel have been shown to be mechanism-based inactivators of CYP2B6-catalyzed efavirenz hydroxylation (Richter et al., 2004; Walsky and Obach, 2007), an in vivo DDI between efavirenz and the inhibitors might be even more pronounced than indicated based on competitive inhibition alone. The AUC ratio of hydroxybupropion to bupropion was reduced by 68% and 90% in the presence of clopidogrel and ticlopidine, respectively, compared with the control, which suggests that both clopidogrel and ticlopidine inhibit the activity of CYP2B6 significantly in vivo as well as in vitro (Turpeinen et al., 2005). Surprisingly, despite the clear inhibition of CYP2B6 by clopidogrel, clotrimazole, itraconazole, sertraline, or ticlopidine, there is no medical documentation on combination therapy utilizing these drugs that may lead to possible side effects. As an exception, there is a report on DDI between efavirenz and itraconazole in a patient with disseminated histoplasmosis and AIDS. The drug combination resulted in persistently elevated urinary histoplasma antigen levels and sub-therapeutic plasma itraconazole concentrations (Koo et al., 2007). Our results and those of Walsky and Obach (2006) suggest that an extensive survey among patients who use CYP2B6-

DMD #23655

metabolized drugs in combination with the potent drug inhibitors is highly desirable. Furthermore, individuals, especially homozygotes, with the 2B6*4 or 2B6*6 allele might be less susceptible to drug interactions resulting from P450 inhibition.

DMD #23655

Acknowledgements

The authors thank Dr. Surendra Negi from the University of Texas Medical Branch for providing the model of CYP2B6dH. We also thank Ling Sun, Pharmacology and Toxicology, UTMB for creating K262R.

DMD #23655

References:

- Bumpus, NN, Chitra Sridar, Kent UM and Hollenberg PF (2005) The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. *Drug Metab Dispos* **33**:795-802.
- Bumpus NN, Kent UM and Hollenberg PF (2006) Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. *J Pharmacol Exp Ther* **318**:345-351.
- Burgess MA and Bodey GP (1972) Clotrimazole (Bay b 5097): In vitro and clinical pharmacological studies. *Antimicrob Ag Chemother* **2**: 423-426
- Dambro MR and Kallgren MA (1988) Drug interactions in a clinic using COSTAR. *Comput Biol Med* **18**:31-38.
- Goodwin ML and Drew RH (2008) Antifungal serum concentration monitoring: An update. *J Antimicrob Chemother* **61**:17-25.
- Guengerich FP (2005) Human cytochrome P450 enzymes, in *Cytochrome P450: Structure, mechanism, and biochemistry*, 3rd ed. (Ortiz de Montellano PR eds), pp 377-530, Plenum press, New York.
- Harlow GR, He YA and Halpert JR (1997) Functional interaction between amino-acid residues 242 and 290 in cytochromes P-450 2B1 and 2B11. *Biochem Biophys Acta* **1338**:259-266.
- Koo HK, Hamill RJ, Andrade RA (2007) Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. *Clin Infect Dis* **45**:77-79

DMD #23655

- Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Mordt TE, Roots I and Brockmoller J (2003) Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. *Pharmacogenetics* **13**:619-626.
- Korhonen LE, Turpeinen M, Rahnasto M, Wittekindt C, Poso A, Pelkonen O, Raunio H and Juvonen RO (2007) New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis. *Br J Pharmacol* **150**:932-942.
- Kramer MA, Tracy TS (2008) Studying cytochrome P450 kinetics in drug metabolism. *Expert Opin Drug Metab Toxicol* **4**:591-603.
- Kumar S, Zhao Y, Sun L, Halpert JR and Muralidhara BK (2007) Rational engineering of human cytochrome P450 2B6 for enhanced expression and stability: Importance of a Leu²⁶⁴ →Phe substitution. *Mol Pharmacol* **72**:1191-1199.
- Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA and Tracy TS (2006) CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. *Drug Metab Dispos* **34**:1966-1975.
- Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. *Pharmacogenetics* **11**:399-415.
- Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M, Schwab M and Zanger UM (2004) Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: Demonstration of phenotypic null alleles. *J Pharm Exp Therap* **311**: 34-43.

DMD #23655

- Lewis DF, Lake BG and Dickins M (2004) Substrates of human cytochromes P450 from families CYP1 and CYP2: Analysis of enzyme selectivity and metabolism. *Drug Metab Drug Interact* **20**:111-142.
- McGinnity DF, Waters NJ, Tucker J and Riley RJ (2008) Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions. *Drug Metab Dispos* **36**:1126-1134.
- Muralidhara BK, Negi S, Chin CC, Braun W and Halpert JR (2006) Conformational flexibility of mammalian cytochrome P450 2B4 in binding imidazole inhibitors with different ring chemistry and side chains. Solution thermodynamics and molecular modeling. *J Biol Chem* **281**:8051-8061.
- Nakajima T, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H and Aoyama T (1994) Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450. *Chem Res Toxicol* **7**:891-896.
- Obach RS, Cox LM and Tremaine LM (2005) Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: An in vitro study. *Drug Metab Dispos* **33**:262-270.
- Oezguen N, Kumar S, Hindupur A, Braun W, Muralidhara BK and Halpert JR (2008) Identification and analysis of conserved sequence motifs in cytochrome P450 family 2: Functional and structural role of a motif ¹⁸⁷RFDYKD¹⁹² in CYP2B enzymes. *J Biol Chem* (<http://www.jbc.org/cgi/doi/10.1074/jbc.M708582200>) E. Pub. May 21
- Pearson JT, Hill JJ, Swank J, Isoherranen N, Kunze KL and Atkins WM (2006) Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations. *Biochemistry* **45**:6341-6353.

DMD #23655

- Rendic S (2002) Summary of information on human CYP enzymes: Human P450 metabolism data. *Drug Metab Rev* **34**:83-448.
- Richter T, Mürdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, Zanger UM (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. *J Pharmacol Exp Ther* **308**:189-197.
- Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Décosterd L, Blievernicht J, Saussele T, Günthard HF, Schwab M, Eichelbaum M, Telenti A and Zanger UM (2007) Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. *Clin Pharmacol Ther* **81**:557-566.
- Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K (2005) Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. *Clin Pharmacol Ther* **77**:553-559
- Walsky RL, Astuccio AV and Obach RS (2006) Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. *J Clin Pharmacol* **46**:1426-1438.
- Walsky RL and Obach RS (2007) A comparison of 2-phenyl-2-(1-piperidiny)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. *Drug Metab Dispos* **35**:2053-2059.
- Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann M and Schwab M (2007) Polymorphic CYP2B6: Molecular mechanism and emerging clinical significance. *Pharmacogenomics* **8**:743-759.

DMD #23655

Footnotes

- a) This work was supported by National Institutes of Health grants ES03619 and Center Grant ES06676. The work was partially presented at Experimental Biology 2008, San Diego, CA.
- b) Reprint requests should be sent to: Jyothi C. Talakad, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093. Email: jtalakad@ucsd.edu
- c) Current Address of Santosh Kumar: Division of Pharmacology and Toxicology, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte St. Kansas City, MO 64108

DMD #23655

Figure Legends

Figure 1. Determination of K_i for inhibition of 7-MFC *O*-deethylation by CYP2B6dH and K262R in the presence of inhibitors (A-H). 7-MFC concentrations included in the assay were 2.5, 5, 10, and 50, μM , and the concentrations of the inhibitors used are provided in the plot. Global fitting of all the data from each experiment was used to obtain K_i . The fitting was done using SpectaLab as described in Materials and Methods.

Figure 2. Representative type I difference spectra of ticlopidine, clopidogrel, sertraline and itaconozole binding (A-D inset). The data were fit to the tight-binding equation, as described in Materials and Methods, to derive the K_s values as listed in Table 2.

Figure 3. Determination of K_i for inhibition of 7-MFC *O*-deethylation by Q172H/K262R in the presence of clopidogrel (A) or sertraline (B). 7-MFC concentrations included in the assay were 25, 50, 100, and 150 μM , and the concentrations of the inhibitors used are provided in the plot. Global fitting of all the data from each experiment was used to obtain K_i . Experiments were done in duplicate. The individual K_i values were: clopidogrel (0.59, 0.63 μM) and sertraline (2.20, 2.16 μM).

Figure 4. Schematic representation of a three-dimensional homology model of CYP2B6dH. The heme is shown in red, while the wild-type Gln-172 and Lys-262 are in green and variant His-172 and Arg-262 in yellow.

Table 1. Determination of K_i and K_s for CYP2B6dH and K262R with clinically important drugs.

| Drugs | K_i (μ M) | | K_s (μ M) | | ΔA_{\max} | |
|--------------|-------------------------|------------------|------------------------------|-----------------|--------------------|-------------------|
| | CYP2B6dH | K262R | CYP2B6dH | K262R | CYP2B6dH | K262R |
| Clopidogrel | 0.07, 0.12 ^a | 0.36, 0.47 | 0.16 ± 0.11 ^b | 0.33 ± 0.14 | 0.026 ± 0.002 | 0.030 ± 0.002 |
| Clotrimazole | 0.15, 0.11 | 0.11, 0.17 | ND | ND | ND | ND |
| Itraconazole | 1.42, 1.34, 1.14 | 4.40, 3.84, 4.34 | 0.07 ± 0.13 | 1.73 ± 0.44 | 0.022 ± 0.003 | 0.021 ± 0.002 |
| Raloxifene | 5.59, 2.60 | 15.8, 17.8 | ND | ND | ND | ND |
| Sertraline | 0.22, 0.38 | 1.70, 1.76 | 0.51 ± 0.16 | 2.06 ± 0.61 | 0.008 ± 0.0005 | 0.02 ± 0.002 |
| Ticlopidine | 0.11, 0.16 | 0.14, 0.12 | 0.28 ± 0.13 | 0.32 ± 0.11 | 0.023 ± 0.001 | 0.025 ± 0.001 |

ND: Not determined

The inhibition was performed using a 7-MFC *O*-deethylation assay in a standard reconstitution system as described in Materials and Methods.

^a K_i values are shown from each independent determination.

^bStandard errors for fit to the tight ligand binding equation. The data are representative of at least two independent determinations.

The variations between the experiments are $\leq 20\%$.

DMD #23655

Table 2. Potential in vivo drug-drug interactions between efavirenz with drug inhibitors

| Inhibitors | Estimated in vivo C_{\max}^a | Predicted in vivo activity (min^{-1}) ^b | |
|--------------|-----------------------------------|---|------------|
| | | CYP2B6dH | K262R |
| NIL | | 2.05 (100) ^c | 3.55 (100) |
| Clopidogrel | 9.3 | 0.04 (1.9) | 0.27 (7.6) |
| Clotrimazole | 3.7 | 0.13 (6.3) | 0.23 (6.5) |
| Itraconazole | 1.9 | 1.16 (57) | 2.84 (80) |
| Raloxifene | 0.003 | 2.06 (100) | 3.55 (100) |
| Sertraline | 0.62 | 0.99 (48) | 3.00 (84) |
| Ticlopidine | 1.6 | 0.30 (15) | 0.47 (13) |

^a C_{\max} of the inhibitors and substrate were obtained from the following literature sources: www.mentalhealth.com/drug/p30-z02.html (sertraline); www.medscape.com/ (raloxifene); www.pharmgkb.org/ (ticlopidine, clopidogrel, and efavirenz); Burgess and Bodey, 1972 (clotrimazole); Goodwin and Drew, 2007 (itraconazole).

^bPredicted in vivo activity was determined using the equation for competitive inhibition. The values for [S] and [I] correspond to the estimated in vivo C_{\max} of efavirenz (13.0 μM) and drug inhibitor, respectively. The K_i values were taken from Table 1, whereas k_{cat} and K_m values were taken from a previous study (Bumpus et al., 2006). Predicted activities for K262R assume that both CYP2B6 alleles are the variant.

^cThe values in parenthesis indicate the % activity.




Figure 1




Figure 2




Figure 3




Figure 4